Xu Han
Impact in
- Pharmacology top 0.5%
- Cancer Research top 5%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Papers in
- Pharmacology 16
Xu Han
257 papers receiving 4.9k citations
Peers
Comparison fields: 5 of 148
- Pharmacology 418
- Cancer Research 610
- Molecular Biology 2.2k
- Complementary and alternative medicine 230
- Oncology 746
Countries citing papers authored by Xu Han
This map shows the geographic impact of Xu Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xu Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xu Han more than expected).
Fields of papers citing papers by Xu Han
This network shows the impact of papers produced by Xu Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xu Han. The network helps show where Xu Han may publish in the future.
Co-authors
The 25 scholars most cited alongside Xu Han, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 15 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 9 | |
| 6 | 2023 | 17 | |
| 7 | 2023 | 43 | |
| 8 | 2021 | 4 | |
| 9 | 2021 | 30 | |
| 10 | Loss of miR-204-5p Promotes Tumor Proliferation, Migration, and Invasion Through Targeting YWHAZ/PI3K/AKT Pathway in Esophageal Squamous Cell Carcinoma | 2020 | 1 |
| 11 | Decreased PTGDS Expression Predicting Poor Survival of Endometrial Cancer by Integrating Weighted Gene Co-Expression Network Analysis and Immunohistochemical Validation | 2020 | 3 |
| 12 | KIF5B-EGFR Fusion: A Novel EGFR Mutation in Lung Adenocarcinoma | 2020 | 2 |
| 13 | Research progress on factors influencing streptozotocin-induced diabetic rat models | 2020 | 2 |
| 14 | 2019 | 23 | |
| 15 | MiR-200a-3p promoted the malignant behaviors of ovarian cancer cells through regulating PCDH9 | 2019 | 2 |
| 16 | 2019 | 6 | |
| 17 | 2018 | 37 | |
| 18 | Methods for Breaking Embryonic Diapause for Germline Transformation of the Silkworm Practical Varieties | 2011 | 1 |
| 19 | Deficit in a Krebs cycle mitochondrial enzyme in brains from patients with Parkinson's disease | 2001 | 2 |
| 20 | Structural Identification of Azadirachtin from the Seeds of Introduced Azadirachta indica A. Juss Planted in China | 2001 | 1 |
About Xu Han
Xu Han is a scholar working on Cancer Research, Pharmacology, Epidemiology, Molecular Biology and Oncology, having authored 278 papers that have together received 5.0k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (26 papers), Neuroendocrine Tumor Research Advances (21 papers), Natural product bioactivities and synthesis (19 papers), Phytochemical Studies and Bioactivities (19 papers), Pancreatic and Hepatic Oncology Research (15 papers), Chromatography in Natural Products (15 papers), Lung Cancer Research Studies (14 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (13 papers). The work is most often cited by research in Pharmacology (418 citations), Cancer Research (610 citations), Molecular Biology (2.2k citations), Complementary and alternative medicine (230 citations) and Oncology (746 citations). Xu Han has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Lina Xu, Yan Qi, Youwei Xu, Lianhong Yin, Jinyong Peng, Xufeng Tao, Kexin Liu, Lingli Zheng, Wenhui Lou and Xuefeng Xu. Their work appears in journals such as Frontiers in Cardiovascular Medicine, British Journal of Pharmacology, Food and Chemical Toxicology, Endocrine Connections and Pancreas.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.